How Well Does CAPTURE Translate?

Quezada, Wilson; Whippo, Beth; Jellen, Patricia A.; Leidy, Nancy Kline; Mannino, David M.; Kim, Katherine J.; Han, MeiLan K.; Houfek, Julia F.; Make, Barry J.; Malley, Karen G.; Meldrum, Catherine A.; Rennard, Stephen I.; Yawn, Barbara P.; Martínez, Fernando J.; Thomashow, Byron; Barr, R. Graham; Bowler, R.P.; Copeland, Rebecca; Dorius, Tim; Ishitani, Karen; Kurland, Marge; Melson, James; Plant, Randel; Schnell, Christina; Shiffermiller, Jason; Stringer, Sonja; Sumnick, Deb; Textor, Kyle B; Underwood, Jennifer; Walsh, John

doi:10.1016/j.chest.2017.03.047

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once again, further research is needed. Fourth, although CAPTURE has been tested and performs well identifying more severe, high-risk cases of COPD in Spanish-speaking patients, 2 sample size precluded testing its performance in milder symptomatic COPD. Finally, CAPTURE is a tool to identify patients requiring further evaluation for COPD; it was not intended to diagnose or evaluate treatment and may detect problems other than COPD that warrant evaluation.…”

Section: Discussionmentioning

confidence: 99%

“…COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) was developed to identify people with severe, high-risk undiagnosed COPD, defined as a forced expiratory volume in 1 second (FEV 1 ) <60% predicted or exacerbation risk, in primary care settings. 1 , 2 This case-finding method uses five simple patient-completed questions and the selective use of peak expiratory flow (PEF) to uncover individuals most likely to benefit from diagnosis and treatment. 1 – 8 The intent is to be as efficient as possible, using PEF selectively based on questionnaire score and reserving spirometry referrals to the subset of patients whose results warrant further diagnostic evaluation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?

Leidy¹,

Martínez²,

Malley³

et al. 2018

COPD

View full text Add to dashboard Cite

BackgroundCOPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) uses five questions and peak expiratory flow (PEF) thresholds (males ≤350 L/min; females ≤250 L/min) to identify patients with a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.70 and FEV1 <60% predicted or exacerbation risk requiring further evaluation for COPD. This study tested CAPTURE’s ability to identify symptomatic patients with mild-to-moderate COPD (FEV1 60%–80% predicted) who may also benefit from diagnosis and treatment.MethodsData from the CAPTURE development study were used to test its sensitivity (SN) and specificity (SP) differentiating mild-to-moderate COPD (n=73) from no COPD (n=87). SN and SP for differentiating all COPD cases (mild to severe; n=259) from those without COPD (n=87) were also estimated. The modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT™) were used to evaluate symptoms and health status. Clinical Trial Registration: NCT01880177, https://ClinicalTrials.gov/ct2/show/NCT01880177?term=NCT01880177&rank=1.ResultsMean age (+SD): 61 (+10.5) years; 41% male. COPD: FEV1/FVC=0.60 (+0.1), FEV1% predicted=74% (+12.4). SN and SP for differentiating mild-to-moderate and non-COPD patients (n=160): Questionnaire: 83.6%, 67.8%; PEF (≤450 L/min; ≤350 L/min): 83.6%, 66.7%; CAPTURE (Questionnaire+PEF): 71.2%, 83.9%. COPD patients whose CAPTURE results suggested that diagnostic evaluation was warranted (n=52) were more likely to be symptomatic than patients whose results did not (n=21) (mMRC >2: 37% vs 5%, p<0.01; CAT>10: 86% vs 57%, p<0.01). CAPTURE differentiated COPD from no COPD (n=346): SN: 88.0%, SP: 83.9%.ConclusionCAPTURE (450/350) may be useful for identifying symptomatic patients with mild-to-moderate airflow obstruction in need of diagnostic evaluation for COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?

Leidy¹,

Martínez²,

Malley³

et al. 2018

COPD

View full text Add to dashboard Cite

show abstract

“… 44–66 Only one studies recruited patients aged >18 years who were former or current smokers or symptomatic smokers, respectively. 61 The incidence of COPD is generally above 20% in studies that include people aged 40 or older with a smoking history and/or persistent symptoms. In contrast, studies that include people aged 18 and above have an incidence of COPD that is typically below 20%.…”

Section: Strategy For Copd Early Detection: Focus On Case-finding App...mentioning

confidence: 99%

“… 62 Quezada performed a study in Spain and demonstrated that the use of the combination of the CAPTURE questionnaire along with a PEF device yielded a higher AUC (0.953) than did the use of the CAPTURE questionnaire only (0.928). 61 The COLA questionnaire was developed by Siddharthan et al and used in combination with a PEF device for identifying individuals with COPD. The COLA questionnaire was used to evaluate respiratory symptoms, smoking or biomass exposure, and functional status.…”

Section: Strategy For Copd Early Detection: Focus On Case-finding App...mentioning

confidence: 99%

Current Progress of COPD Early Detection: Key Points and Novel Strategies

Lin¹,

Cheng²,

Chen³

et al. 2023

COPD

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, with approximately 70% to 80% of adults with COPD being undiagnosed. Patients with undiagnosed COPD are at increased risk of poor outcomes and a worsened quality of life, making early detection a crucial strategy to mitigate the impact of COPD and reduce the burden on healthcare systems. In the past decade, increased interest has been focused on the development of effective strategies and instrument for COPD early detection. However, identifying undiagnosed cases of COPD is still challenging. Both screening and case-finding approaches have been adopted to identify undiagnosed COPD, with case-finding being recommended by the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline and the updated United States Preventive Services Task Force (USPTF) recommendation. Nonetheless, the approaches, criteria, and instruments used for early detection of COPD are varied. However, advances in the taxonomy and risk factors of COPD are continuously being investigated. It is important to continuously assess the current state of knowledge on COPD early detection, given the challenges associated with identifying undiagnosed COPD. This review aims to highlight recent advances in early detection of COPD. To discuss the current challenge and opportunity in COPD early detection, providing an overview of existing literature on COPD case-finding strategies, including the approaches, criteria for subjects, and instruments. The review also summarizes the current progress in COPD case-findings and proposes a COPD case-finding flowchart as an efficient method for identifying at risk COPD patients.

show abstract